Executive summary Tuberculosis can be treated, prevented, and cured. Rapid, sustained
declines in tuberculosis deaths in many countries during the past 50 years provide …

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on
pharmacokinetic, toxicity, and cost considerations. Available data in mice and humans …

BACKGROUND: Optimal drug dosing is important to ensure adequate response to
treatment, prevent development of drug resistance and reduce drug toxicity. The aim of …

For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex
lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular …

Tuberculosis (TB) remains a leading cause of death globally. Dissemination of TB to the
brain results in the most severe form of extrapulmonary TB, tuberculous meningitis (TBM) …

The current tuberculosis (TB) predicament poses numerous challenges and therefore every
incremental scientific work and all positive socio-political engagements, are steps taken in …

Background Intensified antibiotic treatment might improve the outcome of tuberculous
meningitis. We assessed pharmacokinetics, safety, and survival benefit of several treatment …

About 1· 3 million people died of tuberculosis in 2012, despite availability of effective drug
treatment. Barriers to improvements in outcomes include long treatment duration (resulting …